EP1145005A2 - Verfahren zur bestimmung von analyten unter verwendung einer hybriden querflussvorrichtung - Google Patents
Verfahren zur bestimmung von analyten unter verwendung einer hybriden querflussvorrichtungInfo
- Publication number
- EP1145005A2 EP1145005A2 EP00921882A EP00921882A EP1145005A2 EP 1145005 A2 EP1145005 A2 EP 1145005A2 EP 00921882 A EP00921882 A EP 00921882A EP 00921882 A EP00921882 A EP 00921882A EP 1145005 A2 EP1145005 A2 EP 1145005A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- urine
- sample
- lateral flow
- test
- paper
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 210000002700 urine Anatomy 0.000 title claims abstract description 137
- 238000001514 detection method Methods 0.000 title claims abstract description 19
- 238000000034 method Methods 0.000 title claims description 56
- 238000012360 testing method Methods 0.000 claims abstract description 292
- 239000000463 material Substances 0.000 claims description 90
- 239000012530 fluid Substances 0.000 claims description 71
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 33
- 239000011159 matrix material Substances 0.000 claims description 30
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000007787 solid Substances 0.000 claims description 24
- 239000012528 membrane Substances 0.000 claims description 22
- OBHRVMZSZIDDEK-UHFFFAOYSA-N urobilinogen Chemical compound CCC1=C(C)C(=O)NC1CC1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(CC3C(=C(CC)C(=O)N3)C)N2)CCC(O)=O)N1 OBHRVMZSZIDDEK-UHFFFAOYSA-N 0.000 claims description 22
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 21
- 230000004044 response Effects 0.000 claims description 19
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 18
- 239000008103 glucose Substances 0.000 claims description 18
- 239000007844 bleaching agent Substances 0.000 claims description 17
- 239000003153 chemical reaction reagent Substances 0.000 claims description 16
- 239000012491 analyte Substances 0.000 claims description 15
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 239000007800 oxidant agent Substances 0.000 claims description 15
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 12
- 229940109239 creatinine Drugs 0.000 claims description 12
- 239000000872 buffer Substances 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 claims description 10
- ZCDOYSPFYFSLEW-UHFFFAOYSA-N chromate(2-) Chemical compound [O-][Cr]([O-])(=O)=O ZCDOYSPFYFSLEW-UHFFFAOYSA-N 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 239000007983 Tris buffer Substances 0.000 claims description 9
- 210000001124 body fluid Anatomy 0.000 claims description 9
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 9
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- -1 TABS Chemical compound 0.000 claims description 8
- 239000011575 calcium Substances 0.000 claims description 8
- 229910052791 calcium Inorganic materials 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 8
- XEYBHCRIKKKOSS-UHFFFAOYSA-N disodium;azanylidyneoxidanium;iron(2+);pentacyanide Chemical group [Na+].[Na+].[Fe+2].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].[O+]#N XEYBHCRIKKKOSS-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- 235000010323 ascorbic acid Nutrition 0.000 claims description 7
- 239000011668 ascorbic acid Substances 0.000 claims description 7
- 229960005070 ascorbic acid Drugs 0.000 claims description 7
- 210000004209 hair Anatomy 0.000 claims description 7
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 claims description 7
- 210000003296 saliva Anatomy 0.000 claims description 7
- 235000010339 sodium tetraborate Nutrition 0.000 claims description 7
- 210000004243 sweat Anatomy 0.000 claims description 7
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 claims description 6
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 claims description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 229940083618 sodium nitroprusside Drugs 0.000 claims description 5
- 229910021578 Iron(III) chloride Inorganic materials 0.000 claims description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 claims description 4
- 229910021538 borax Inorganic materials 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 230000002496 gastric effect Effects 0.000 claims description 4
- 230000005484 gravity Effects 0.000 claims description 4
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 239000004328 sodium tetraborate Substances 0.000 claims description 4
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 claims description 3
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 claims description 3
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 claims description 3
- ACERFIHBIWMFOR-UHFFFAOYSA-N 2-hydroxy-3-[(1-hydroxy-2-methylpropan-2-yl)azaniumyl]propane-1-sulfonate Chemical compound OCC(C)(C)NCC(O)CS(O)(=O)=O ACERFIHBIWMFOR-UHFFFAOYSA-N 0.000 claims description 3
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 claims description 3
- BZSXEZOLBIJVQK-UHFFFAOYSA-N 2-methylsulfonylbenzoic acid Chemical compound CS(=O)(=O)C1=CC=CC=C1C(O)=O BZSXEZOLBIJVQK-UHFFFAOYSA-N 0.000 claims description 3
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 3
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 claims description 3
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 claims description 3
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 claims description 3
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 claims description 3
- XNPKNHHFCKSMRV-UHFFFAOYSA-N 4-(cyclohexylamino)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCNC1CCCCC1 XNPKNHHFCKSMRV-UHFFFAOYSA-N 0.000 claims description 3
- LOJNFONOHINEFI-UHFFFAOYSA-N 4-[4-(2-hydroxyethyl)piperazin-1-yl]butane-1-sulfonic acid Chemical compound OCCN1CCN(CCCCS(O)(=O)=O)CC1 LOJNFONOHINEFI-UHFFFAOYSA-N 0.000 claims description 3
- VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000007991 ACES buffer Substances 0.000 claims description 3
- 239000007988 ADA buffer Substances 0.000 claims description 3
- 101150035093 AMPD gene Proteins 0.000 claims description 3
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 3
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 claims description 3
- 239000007992 BES buffer Substances 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims description 3
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000008000 CHES buffer Substances 0.000 claims description 3
- 239000007995 HEPES buffer Substances 0.000 claims description 3
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims description 3
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 claims description 3
- 102000001554 Hemoglobins Human genes 0.000 claims description 3
- 108010054147 Hemoglobins Proteins 0.000 claims description 3
- 239000007993 MOPS buffer Substances 0.000 claims description 3
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 claims description 3
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 claims description 3
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 claims description 3
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims description 3
- 239000007990 PIPES buffer Substances 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 3
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 claims description 3
- 239000007994 TES buffer Substances 0.000 claims description 3
- 239000007997 Tricine buffer Substances 0.000 claims description 3
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 claims description 3
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims description 3
- 239000007998 bicine buffer Substances 0.000 claims description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 claims description 3
- 239000000920 calcium hydroxide Substances 0.000 claims description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 claims description 3
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 claims description 3
- CDMADVZSLOHIFP-UHFFFAOYSA-N disodium;3,7-dioxido-2,4,6,8,9-pentaoxa-1,3,5,7-tetraborabicyclo[3.3.1]nonane;decahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.[Na+].[Na+].O1B([O-])OB2OB([O-])OB1O2 CDMADVZSLOHIFP-UHFFFAOYSA-N 0.000 claims description 3
- 229960000443 hydrochloric acid Drugs 0.000 claims description 3
- 235000011167 hydrochloric acid Nutrition 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 229960000448 lactic acid Drugs 0.000 claims description 3
- 235000016337 monopotassium tartrate Nutrition 0.000 claims description 3
- 229960005222 phenazone Drugs 0.000 claims description 3
- 229960003742 phenol Drugs 0.000 claims description 3
- 239000010452 phosphate Substances 0.000 claims description 3
- 229960004838 phosphoric acid Drugs 0.000 claims description 3
- 235000011007 phosphoric acid Nutrition 0.000 claims description 3
- KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 claims description 3
- IWZKICVEHNUQTL-UHFFFAOYSA-M potassium hydrogen phthalate Chemical compound [K+].OC(=O)C1=CC=CC=C1C([O-])=O IWZKICVEHNUQTL-UHFFFAOYSA-M 0.000 claims description 3
- 229940086065 potassium hydrogentartrate Drugs 0.000 claims description 3
- 150000003873 salicylate salts Chemical class 0.000 claims description 3
- BAZAXWOYCMUHIX-UHFFFAOYSA-M sodium perchlorate Chemical compound [Na+].[O-]Cl(=O)(=O)=O BAZAXWOYCMUHIX-UHFFFAOYSA-M 0.000 claims description 3
- 229910001488 sodium perchlorate Inorganic materials 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 3
- 108010000849 leukocyte esterase Proteins 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 238000001228 spectrum Methods 0.000 claims 4
- 238000001035 drying Methods 0.000 claims 3
- 239000007989 BIS-Tris Propane buffer Substances 0.000 claims 2
- HHKZCCWKTZRCCL-UHFFFAOYSA-N bis-tris propane Chemical compound OCC(CO)(CO)NCCCNC(CO)(CO)CO HHKZCCWKTZRCCL-UHFFFAOYSA-N 0.000 claims 2
- 238000010030 laminating Methods 0.000 claims 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 22
- 239000003814 drug Substances 0.000 abstract description 22
- 238000012864 cross contamination Methods 0.000 abstract description 9
- 231100000027 toxicology Toxicity 0.000 abstract description 2
- 238000012123 point-of-care testing Methods 0.000 abstract 1
- 239000000123 paper Substances 0.000 description 165
- 239000000243 solution Substances 0.000 description 100
- 239000000523 sample Substances 0.000 description 86
- 238000006243 chemical reaction Methods 0.000 description 68
- 239000000020 Nitrocellulose Substances 0.000 description 46
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 46
- 229920001220 nitrocellulos Polymers 0.000 description 46
- 239000000126 substance Substances 0.000 description 29
- 239000002250 absorbent Substances 0.000 description 26
- 230000002745 absorbent Effects 0.000 description 26
- 239000000203 mixture Substances 0.000 description 26
- 239000003086 colorant Substances 0.000 description 25
- 239000007788 liquid Substances 0.000 description 23
- 229920006395 saturated elastomer Polymers 0.000 description 18
- 238000003556 assay Methods 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000003255 drug test Methods 0.000 description 16
- 230000009471 action Effects 0.000 description 14
- 239000012153 distilled water Substances 0.000 description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 239000004033 plastic Substances 0.000 description 11
- 229920003023 plastic Polymers 0.000 description 11
- 238000012216 screening Methods 0.000 description 11
- 239000003365 glass fiber Substances 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 239000000376 reactant Substances 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 8
- 238000000338 in vitro Methods 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 7
- 238000012790 confirmation Methods 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 7
- 238000005516 engineering process Methods 0.000 description 7
- 230000001590 oxidative effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 6
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 6
- 241000972773 Aulopiformes Species 0.000 description 5
- 239000000853 adhesive Substances 0.000 description 5
- 230000001070 adhesive effect Effects 0.000 description 5
- 238000003018 immunoassay Methods 0.000 description 5
- 238000005470 impregnation Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 235000019515 salmon Nutrition 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 229920002301 cellulose acetate Polymers 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 239000002117 illicit drug Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000344 soap Substances 0.000 description 4
- 239000007790 solid phase Substances 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011449 brick Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 238000007598 dipping method Methods 0.000 description 3
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 3
- 235000002639 sodium chloride Nutrition 0.000 description 3
- 239000000057 synthetic resin Substances 0.000 description 3
- 229920003002 synthetic resin Polymers 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 3
- 229920002554 vinyl polymer Polymers 0.000 description 3
- CIWBSHSKHKDKBQ-UHFFFAOYSA-N 2-(1,2-dihydroxyethyl)-3,4-dihydroxy-2h-furan-5-one Chemical compound OCC(O)C1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-UHFFFAOYSA-N 0.000 description 2
- NUIURNJTPRWVAP-UHFFFAOYSA-N 3,3'-Dimethylbenzidine Chemical compound C1=C(N)C(C)=CC(C=2C=C(C)C(N)=CC=2)=C1 NUIURNJTPRWVAP-UHFFFAOYSA-N 0.000 description 2
- VYWYYJYRVSBHJQ-UHFFFAOYSA-N 3,5-dinitrobenzoic acid Chemical compound OC(=O)C1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1 VYWYYJYRVSBHJQ-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 239000001836 Dioctyl sodium sulphosuccinate Substances 0.000 description 2
- 206010013654 Drug abuse Diseases 0.000 description 2
- 239000004366 Glucose oxidase Substances 0.000 description 2
- 108010015776 Glucose oxidase Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000005708 Sodium hypochlorite Substances 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003599 detergent Substances 0.000 description 2
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 210000004905 finger nail Anatomy 0.000 description 2
- 235000019420 glucose oxidase Nutrition 0.000 description 2
- 229940116332 glucose oxidase Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- RDOWQLZANAYVLL-UHFFFAOYSA-N phenanthridine Chemical compound C1=CC=C2C3=CC=CC=C3C=NC2=C1 RDOWQLZANAYVLL-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 239000010454 slate Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 description 2
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 2
- PZBRPDUUWGYUTE-IWSIBTJSSA-M sodium;2-[(z)-(3,5-dibromo-4-hydroxy-2-methylphenyl)-(3,5-dibromo-2-methyl-4-oxocyclohexa-2,5-dien-1-ylidene)methyl]benzenesulfonate Chemical compound [Na+].CC1=C(Br)C(=O)C(Br)=C\C1=C(C=1C(=CC=CC=1)S([O-])(=O)=O)/C1=CC(Br)=C(O)C(Br)=C1C PZBRPDUUWGYUTE-IWSIBTJSSA-M 0.000 description 2
- BAVBEHWEOJMHDS-UHFFFAOYSA-M sodium;4-[3-(4-hydroxy-2-methyl-5-propan-2-ylphenyl)-1,1-dioxo-2,1$l^{6}-benzoxathiol-3-yl]-5-methyl-2-propan-2-ylphenolate Chemical compound [Na+].C1=C(O)C(C(C)C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C(=CC([O-])=C(C(C)C)C=2)C)=C1C BAVBEHWEOJMHDS-UHFFFAOYSA-M 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- CVSUAFOWIXUYQA-UHFFFAOYSA-M 2,6-Dichlorophenolindophenol sodium salt Chemical group [Na+].C1=CC([O-])=CC=C1N=C1C=C(Cl)C(=O)C(Cl)=C1 CVSUAFOWIXUYQA-UHFFFAOYSA-M 0.000 description 1
- CCBICDLNWJRFPO-UHFFFAOYSA-N 2,6-dichloroindophenol Chemical compound C1=CC(O)=CC=C1N=C1C=C(Cl)C(=O)C(Cl)=C1 CCBICDLNWJRFPO-UHFFFAOYSA-N 0.000 description 1
- IEQAICDLOKRSRL-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-dodecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO IEQAICDLOKRSRL-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-UHFFFAOYSA-N 3-ethyl-2-[(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C1=NN=C1SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-UHFFFAOYSA-N 0.000 description 1
- WXMQHPKQCPCDQO-UHFFFAOYSA-N 4-dimorpholin-4-ylphosphorylmorpholine Chemical compound C1COCCN1P(N1CCOCC1)(=O)N1CCOCC1 WXMQHPKQCPCDQO-UHFFFAOYSA-N 0.000 description 1
- NDBJTKNWAOXLHS-UHFFFAOYSA-N 4-methoxybenzenediazonium Chemical compound COC1=CC=C([N+]#N)C=C1 NDBJTKNWAOXLHS-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N N-Lauroylsarcosine Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920001131 Pulp (paper) Polymers 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229920006243 acrylic copolymer Polymers 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- XKNKHVGWJDPIRJ-UHFFFAOYSA-N arsanilic acid Chemical compound NC1=CC=C([As](O)(O)=O)C=C1 XKNKHVGWJDPIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000012461 cellulose resin Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000007705 chemical test Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000004851 dishwashing Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000007877 drug screening Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 239000003845 household chemical Substances 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 238000013101 initial test Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- HYYBABOKPJLUIN-UHFFFAOYSA-N mefenamic acid Chemical compound CC1=CC=CC(NC=2C(=CC=CC=2)C(O)=O)=C1C HYYBABOKPJLUIN-UHFFFAOYSA-N 0.000 description 1
- 229960003464 mefenamic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- CEQFOVLGLXCDCX-WUKNDPDISA-N methyl red Chemical compound C1=CC(N(C)C)=CC=C1\N=N\C1=CC=CC=C1C(O)=O CEQFOVLGLXCDCX-WUKNDPDISA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000007793 ph indicator Substances 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- HLWRUJAIJJEZDL-UHFFFAOYSA-M sodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetate Chemical compound [Na+].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC([O-])=O HLWRUJAIJJEZDL-UHFFFAOYSA-M 0.000 description 1
- HFQQZARZPUDIFP-UHFFFAOYSA-M sodium;2-dodecylbenzenesulfonate Chemical compound [Na+].CCCCCCCCCCCCC1=CC=CC=C1S([O-])(=O)=O HFQQZARZPUDIFP-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- BJORNXNYWNIWEY-UHFFFAOYSA-N tetrahydrozoline hydrochloride Chemical compound Cl.N1CCN=C1C1C2=CC=CC=C2CCC1 BJORNXNYWNIWEY-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 229940028445 visine Drugs 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
Definitions
- the field of this invention is a test device which may be used for adulteration testing, that is, to determine whether body fluid samples submitted for drug testing have been tampered with or "adulterated”.
- the invention may also be used in the field of in vitro diagnostics chemistry testing.
- the test device of the present invention makes use of lateral flow mechanics and dry chemistry techniques to present surprising and unexpected multiple advantages over the prior art. This device can be utilized in "Point of Care” ("POC”) products.
- POC Point of Care
- the first utilizes an "in vivo” technique in which the user consumes the adulterant.
- the second technique utilizes an "in vitro” method in which the abuser adds the adulterant directly to the urine specimen submitted for testing.
- the drug testing procedure involves two distinct parts.
- the initial segment is a panel of screening tests for the individual drugs. If a positive result is obtained in any of these initial tests, then a confirmation assay is performed for each drug that screened positive.
- Most adulteration techniques are aimed at the screening process, because of the inherent fragile nature of these inexpensive assays which adapt well to rapid, automated analysis techniques. All screening tests utilize antibody/antigen reactions quantified via an enzyme indicator.
- confirmation assays are labor and time intensive, highly accurate, expensive, and more difficult to adulterate.
- the positive screen has already raised a red flag, thereby drawing attention to the sample.
- the confirmation analysis utilizes GC-MS (gas chromatography mass spectrometry) testing which is considered the "gold standard" for drug assays scientifically and legally.
- the "in vivo" methods function in one of three ways. These include dilution of the analyte of interest to a level below that required for a positive result, decreasing the time required to eliminate the consumed drug, or consuming a compound that will interfere with the screening method. Dilution is effected by consuming a large volume of liquid together with a diuretic to speed elimination of urine, and a B vitamin to add yellow color to the urine sample.
- Some commercial in viva dilution products or "flushes” are sold under the following names: Carbo Clean, Test Pure, Kleen Test, Quick Flush, Naturally Klean, Test Free, UA Flush, Zydot's Special Blend, Daily Pure, Vale's Quick Clean, Test'n, and UR'n Kleen. Decreasing the elimination time will often enable the weekend drug user to avoid testing positive on a Monday morning drug test. This is accomplished by consuming acidic liquids (e.g. acidic fruit juices or ammonium chloride) to speed up elimination of basic drugs, or consuming basic liquids to speed up elimination of acidic drugs. Examples of an internally ingested substance which will disrupt the screening test procedure include aspirin and mefenamic acid, a prescription analgesic pain killer.
- acidic liquids e.g. acidic fruit juices or ammonium chloride
- Products affecting the screening process include many household products (i.e. all types of cleaners including hand, clothes and dishwashing detergents and soaps, table salt, bleach (sodium hypochlorite), fingernail polish remover, vinegar, Drano, liquid plumber, sodium bicarbonate, Visine, fingernail polish, swimming pool cleaning chemicals and acid), or specialty products sold commercially as adulterants (i.e. Urine Luck, Purafyzit, Urine Sured, and THC Free are acid-based products, UrinAid and Clear Choice are glutaraldehyde containing products, Amber- 13 contains sulfides, Mary Jane Super Clean
- Substitution, or using a clean urine sample supplied by a third party can be either in vivo or in vitro adulteration.
- participants hide a clean urine in their clothing and put it into the specimen collection container (in vitro).
- Individuals requiring more stealth including those giving observed collections may substitute via the in viva technique which requires putting the clean urine into the subject's bladder using a catheter.
- Illicit drug users have learned to falsify urine screening tests by in vitro adulteration of urine samples by the addition of several readily available agents, including household products (soap, bleach, etc.), hydrogen peroxide, and commercially available adulteration products, such as "UrinAid" (glutaraldehyde).
- UrinAid glutaraldehyde
- Collection facilities try to prevent in vitro adulteration or substitution by recording the temperature of the sample as soon as it is collected. It must fall inside the very narrow range of 90.5 to 99.8 degrees Fahrenheit. They also may require subjects to leave excessive clothing out of the collection room, and provide no hot water which prevents dilution of the sample with water. Obviously, however, it is very easy to secret small quantities of adulterating substances into the collection room. As little as a pinch of salt or a drop or two of glutaraldehyde or acid will affect most test screens. Because the effective amounts of most adulterants are very small, even observed collection as required by the military and criminal justice system can be defeated using the in vitro technique. On the other hand, collection facilities currently have no weapons to detect in vivo adulterants, because they are consumed by the drug user several hours or days prior to collection of the sample. Currently only certain forms of adulteration as already mentioned can be detected in the laboratory.
- FPIA fluorescent polarization immunoassay
- RIA radioimmunoassay
- EIA enzyme immunoassay
- CEDIA KIMS: Antibody/agglutination
- Toxicology and clinical chemistry literature includes numerous studies on the effects of adulterants on the screening technologies and the recommendation to test for their presence in urine samples. References include Mikkelsen and Ash, "Adulterants Causing False Negatives In Illicit Drug Testing", Clin. Chem. 34/11, 2333-2336 (1988); and Warner, "Interference of Common Household Chemicals In Immunoassay Methods For Drugs Of Abuse", Clin. Chem., 35/4, 648-651 (1989).
- DAU Drugs of Abuse
- test strips i.e. dry chemistry dipsticks, or on-site test modules utilizing thin layer chromatography in a lateral flow format, or other technology similar to the test strip
- liquid chemistry reagents for use in the detection of various adulterants or parameters which indicate adulteration of immunoassays designed to detect DAU in aqueous fluids, including urine, saliva, serum, blood, sweat extracts, and liquid homogenates of hair.
- Enzyme and antigen/antibody reaction kinetics are related to the rate of change in analytical, biological systems. The variables that affect this rate of change include concentration of reactants and product, temperature, pH, ionic strength, buffer strength, and other parameters. Many commercial and household adulterants dramatically affect the parameters noted above.
- the device of the present invention clearly indicates whether the adulterant is present in the sample matrix and thus prevents a false positive or false negative result if only the drug test were relied upon.
- the adulteration underground network produces two to five new methods to fool the drug tests each year.
- drug testing facilities are forced to maintain a constant vigil for any unusual results.
- GC-MS a confirmation, assay, is performed to verify the urines that screen positive for drugs of abuse.
- the GC-MS analysis costs 100 times as much as the initial screen ($100 vs $1).
- This invention provides a previously unavailable dry chemistry method for determining adulteration of a test sample by measuring the presence of glutaraldehyde as required currently by the Department of Transportation, Nuclear Regulatory Commission, College of American Pathologist's Forensic Urine Drug Testing program, and the U.S. Department of Health and Human Service's SAMSHA program on all urine assayed for drugs of abuse under their protocols.
- POC test devices are utilized in a wide variety of ways. For instance, in the drugs of abuse testing field, POC devices utilize a lateral flow format to detect drugs of abuse. That is to say, that a few drops of urine specimen is added to one end of lateral flow device material. The urine then migrates to the opposite end of the material. During this process the urine will interact with chemicals or reactants in that are impregnated into the paper and yield a detectable response.
- urinalysis dipsticks utilize a dry chemistry urine dipstick. Dipsticks used in this manner typically have a plastic backing 5 mm wide by 70 mm long with several small pads 5 mm by 5mm
- the strips are removed and the reaction occurring on the chemically impregnated test pads is visually observed for a specific color reaction. That color is then compared to a color chart that has a range of colors specific to the test pad which correspond to a particular concentration of the analyte of interest.
- One of many drawbacks of this type of method is that the urine which is left on the dipstick mixes with a chemically impregnated test pad and then crosses over to another test pad. In the devices of the prior art, this cross over contamination or cross-contamination could interfere with the chemical reaction of the second test pad and cause erroneous results.
- the dipstick of the prior art by being dipped into the urine sample, could alter the integrity of the urine by contamination of the urine with the chemically impregnated test pads. This contamination could have legal implications in DOA testing where additional testing on the sample may be required.
- POC devices are being used in an ever increasing rate as an inexpensive alternative to physician and hospital visits. Many POC devices are used once and discarded. It is an object of the present invention to improve accuracy, precision, prevent cross- contamination or carry over, and reduce cost to the end user.
- the device and method of the present invention allow for the detection of adulterants and other analytes effectively with a single assay using therefore according the user an easy and convenient manner by which to make a determination of the presence or absence of the analyte in samples.
- the unique device of the present invention also eliminates interference from cross over of reagents or fluid from one test pad to another, a problem experienced with prior art dipsticks. The delivery of a known amount of fluid to the reaction pad improves precision, accuracy, and sensitivity of the test device. Applicant's invention also fills the need for a rapid, manual determination of adulteration.
- the present invention relates to test devices for detecting the presence of an adulterant or other analyte in a liquid test sample such as urine, the device manufacture, and use.
- the invention may also be used to detect analytes typically associated with clinical chemistry.
- the present invention provides dry chemistry test strips (i.e. dipsticks, or dry chemistry and lateral flow [thin layer chromatography] test means) for use in the detection of adulteration of human, biological samples (e.g. urine, blood, serum, saliva, sweat extracts, and hair homogenates) to be tested for DAUs via immunoassays.
- This invention achieves this goal by measuring the absence or presence of adulterant or other analyte, or by testing for parameters which would indicate the presence of an adulterant in a test sample.
- One embodiment of the invention is a unique device which eliminates cross-contamination between reactant areas such as test pads on dipsticks by the use of both dipstick test pad and lateral flow device technology.
- the present invention encompasses a method that can utilize several different techniques.
- the techniques employ a manual method using dry chemistry dipsticks and a method of combining dry chemistry dipstick reactant areas (test pads) with lateral flow thin layer chromatography.
- the present invention uses a novel method of lateral flow in combination with the test pad.
- the lateral flow and dry chemistry dipstick hybrid device is a rapid test that uses absorbent medium such as paper which has been impregnated with the chemical formulation (the test pad) that will detect various analytes from bodily fluid samples, such as urine, placed on top of a lateral flow medium.
- the reaction takes place within the lateral flow material (which can also be used as support material).
- the reaction takes place on the dry chemical test paper, not the plastic backing or support material.
- a few drops of urine specimen can be added to one end of lateral flow device material (usually a paper matrix of some type, nitrocellulose, for instance).
- the urine migrates to the opposite end of the material.
- the urine will interact with chemicals or reactants that are impregnated in the paper matrix to yield a detectable response.
- the reaction takes place inside of the lateral flow material.
- One advantage of the lateral flow technology is that the lateral flow material will limit the maximum amount of sample which will be used. The amount of sample used will be the same as long as the material is the same. This advantage allows for improved precision and accuracy.
- Dry chemistry dipsticks use a chemically impregnated test pad.
- the dipsticks typically have a plastic backing 5 mm wide by 70 mm long with several small pads (each representing a different test) 5 mm by 5 mm (generally made of chemically impregnated filter paper) laminated onto the plastic backing with an adhesive. These strips are then dipped into a container typically filled with urine. The strips are removed and the reactions upon the chemically impregnated test pads are visually observed for specific color reactions. The test pads are then compared to a color chart that has a range of colors specific to the test pads, which correspond to a particular concentration of the analyte of interest. The reaction takes place in the test pad not on the backing or support material.
- the dipstick technology does not quantitate the volume of liquid sample used.
- a filter paper (or other suitable material capable of absorbing chemicals), after impregnation with chemicals (the test pad) that will detect the parameter or analyte of interest, is placed on a lateral flow medium, such as nitrocellulose paper, glass fiber paper, or other suitable wicking material.
- the wicking material delivers the test sample to the impregnated paper.
- the device thus has both dipstick test pads (the filter paper) and lateral flow characteristics and will be referred to herein as the Lateral
- LFD Hybrid Flow Hybrid
- the LFD Hybrid device has a quantitative to qualitative assay range. The results are evaluated via one of two categories: negative and positive or given in quantitative ranges. For example, a pH result could be determined from a pH range of 3.0 to 1 1.0 pH units in increments of 0.1 pH units.
- FIG. 1 and IB are side views of the preferred embodiment of the test device.
- FIG. 1 A is a top plan view of the preferred embodiment of the test device.
- FIG. 2 is a side view that depicts the lateral flow material resting on the top edge of the test pad of the test device.
- FIG. 3 is a side view of the test device with the lateral flow material in vertical contact with the test pad.
- An embodiment of the present invention is a device in the form of a dry chemistry dipstick or LFD Hybrid for the detection of adulterants in sample matrices consisting of urine or other biological specimens.
- the assay device includes an adulteration reagent comprising buffer(s) and color indicator(s). Buffering of the reactants is critical to the adulteration reagent, because pH plays a vital role in the reaction kinetics.
- adulteration reagent components are impregnated on a test strip pad composed of solid, absorbent carrier(s) matrix, usually known as test pads.
- test pads are typically affixed to a solid support (usually plastic).
- the dipstick is then submerged in the liquid test sample, removed, and a measurable (i.e. visible) response is observed.
- the dry chemistry test pad is chemically impregnated in the manner used with the dipstick. The test pad is then placed in fluid
- lateral flow paper such as nitrocellulose
- the adulteration reagent used in the dipstick and the LFD Hybrid comprise one or more compositions which produce a detectable manifestation of the presence or absence of a particular chemical component.
- the chemical component being detected is that adulterant (e.g., glutaraldehyde, chromate, bleach such as household bleach, oxidant, nitrite) or an indication of adulteration (e.g., altered pH, specific gravity, creatinine) or a chemistry parameter (e.g. calcium, glucose, urobilinogen, bilirubin, protein, ketone, leucocyte esterase) in the sample.
- the response can be in the form of the appearance or disappearance of a color, or the changing of one color to another. Said measurable response may also be evidenced by a change in the amount of light reflected or absorbed during the reaction of interest.
- Those skilled in the art are familiar with methods of detectable responses.
- One feature of the present invention are newly discovered indicators for glutaraldehyde in urine: sodium nitroprusside, ferric chloride, salicylates, phenol, antipyrine, and sodium nitroprusside analogs.
- Suitable buffers may include any of the following (referred to here by their commonly used acronyms): citrate, borate, borax, sodium tetraborate decahydrate, sodium perchlorate, sodium chlorate, sodium carbonate, tris base, tris acid, MES, BIS-TRIS, ADA, ACES, PIPES, MOPSO, BIS-TRIS
- PROPANE PROPANE, BES, MOPS, TES, HEPES, DIPSO, MOBS, TAPSO, TRIZMA, HEPPSO,
- AMPSO CHES, CAPSO, AMP, CAPS, CABS, hydrochloric acid, phosphoric acid, lactic acid, potassium hydrogen tartrate, potassium hydrogen phthalate, calcium hydroxide, phosphate, bicarbonate, sodium hydroxide, potassium hydroxide, oxalate or succinate.
- Manufacture of the dry chemistry dipsticks and the test pads used on the LFD Hybrid may require the addition of thickeners as taught in the art.
- Some compounds commonly used for this purpose include: polyvinylpyrrolidone, algin, carragenin, casein, albumin, methyl cellulose, and gelatin. The typical range of concentration for these thickeners is about 0.5 to 5.0 g. per 100 ml.
- Wetting agents or surfactants are also typically used in dry chemistry. For dry chemistry applications, wetting agents aid in even distribution of the chemicals and promote even color development. Acceptable wetting agents can be hydrophilic polymers, or cationic, anionic, amphoteric, or nonionic species.
- wetting agents include sodium dodecyl-benzene sulphonate, sodium lauryl sulphate, benzalkonium chloride, N-lauroylsarcosine sodium salt, Brij-35, Tween 20, Triton X-100, dioctyl sodium sulphosuccinate, and polyethylene glycol 6000.
- Wetting agents can be added to dipstick impregnation solutions in amounts of 0.5% to 5.0%, and 0.1% to 1.0% in liquid reagents.
- Color enhancers may be required or used such as sucrose, lactose, glucose or other compounds. Color enhancement can be defined as intensification and /or alteration in some manner the color that is produced by the reaction to improve the measurement of the detectable response.
- the dry chemistry test strips/test pads for the present invention can utilize any form of absorbent, solid phase carrier including paper, filter paper, filter membrane to include polyvinyl, polyvinylidene fluoride, polyester polyethersulfone, polytetrafluoroethylene, cellulose acetate, cellulose nitrate, cellulose acetate, nylon, cellulose esters, acrylic copolymer, polypropylene, nitrocellulose, mixed esters of cellulose nitrate and cellulose acetate, polycarbonate, teflon, glass fiber paper, crepe filter paper, wood pulp paper, cotton filter paper, ashless filter pulp, cotton linter filter paper, cellulose, synthetic resin, fleeces, or other suitable absorbent material in conjunction with liquid solutions of reagent compositions in volatile solvents.
- the test strip/test pad material should be an absorbent
- wicking material that permits migration of sample up the solid absorbent test pad and allows analytes and reactants to react.
- the impregnation may be in one or more steps.
- Each impregnation may contain one or more of the chemical compounds making up the assay reagent composition; the exact procedure is dictated by the inter-reactivity of the assay constituents and the order in which they may have to react with the analyte of interest.
- the LFD Hybrid lateral flow material can utilize any form of absorbent, solid phase carrier that is capable of transporting a fluid. These can include filter paper, cellulose or synthetic resins. More specifically, the lateral flow material can include cellulose, cellulose acetate, nitrocellulose, mixed ester, teflon, polyvinylidene difluoride (PVDF), polytetrafluoroethylene (PTFE), polysulfone, cotton linter, non-woven rayon, glass fiber, nylon, ion exchange or other suitable membranes or solid support.
- the solid phase carrier that has the capabilities of transporting a fluid from one site to another across a distance of at least 5 to 10 mm.
- the lateral flow material may also serve as a support material.
- the solid phase carrier of the dipstick is dried, cut into strips, glued to a support structure (usually a flexible, flat, plastic stick) as part of a "sandwich" composed of a handle, a test pad, and a synthetic resin film and/or a fine-mesh material in the manner described in German Pat. No, 2,118,455, incorporated herein by reference.
- the impregnated test pad is attached to or put into contact with lateral flow material.
- the present invention may be combined with the water-stable film as taught in U.S. Pat. No. 3,530,957, incorporated herein by reference, to produce a dipstick in which the excess sample fluid can be wiped off in order to improve the accuracy and precision of the results.
- the LFD Hybrid comprises some or all of the following: test pad (usually filter paper) impregnated with buffers, and reaction components that can include indicators, surfactants or other ingredients needed for the test pad to be reactive to an analyte of interest.
- test pad usually filter paper
- reaction components that can include indicators, surfactants or other ingredients needed for the test pad to be reactive to an analyte of interest.
- the test pad is then placed in fluid contact with the lateral flow material. This device is then exposed to a fluid. The fluid then migrates to the location of the test pad, saturates the test pad, and the reaction takes place.
- the liquid sample 1 is introduced through pipetting, dropping, dipping, contacting or exposing the liquid sample 1 in some manner to the sample introduction area 2 of the lateral flow material 3.
- the sample 1 then migrates (as illustrated by the arrows) from the sample introduction area 2 to opposite end of the lateral flow material 4. While the sample 1 is flowing from the sample introduction area 2 to the opposite end 4 of the lateral flow material 3, the chemically impregnated dipstick test pad
- FIG. 2 depicts the lateral flow material 4 as placed onto the top edge of the chemically impregnated dipstick test pad 5.
- the lateral flow material 4 is placed next to the chemically impregnated dipstick test pad 5 (but, still in direct (fluid) contact with the lateral flow material 3).
- FIG. IB illustrates multiple test pads 5 which are in contact with the lateral material 4. As the fluid migrates from one pad to the next, no cross over from one test pad 5 to the next occurs, thus, preventing cross contamination.
- the pads allow for a specific and constant amount of fluid to reach each pad, enhancing precision, accuracy, and specificity.
- concentrations of the components in the following examples can be varied to suit the dipstick device format, dependent upon paper type, or use of semi-permeable membrane or other suitable material. Further, the concentrations of the constituents can be varied to suit the LFD Hybrid device format, e.g. dependent upon paper type, and inclusion of semi-permeable membranes or other innovations utilized in dry chemistry technology.
- the color charts referred to in the following examples can be made in-house using standard techniques available to those skilled in the art. Alternative sources are available.
- EXAMPLE 1 This example illustrates a dry chemistry dipstick (test strip) with a solid carrier for the adulteration detection of glutaraldehyde in samples submitted for drugs of abuse analysis and its use.
- Filter paper was successively impregnated with the following solutions and dried at 25 degrees C:
- Solution 1 Disodium phosphate (sodium phosphate dibasic) 200.0 g
- Sodium nitroprusside 20.0 g distilled water added to 1 L total volume of solution pH of the solution should be between 7.5 and 11.5
- the dipstick comprised a paper carrier or solid matrix incorporated with the composition of Solution 1.
- a piece of Schleicher & Schuell (Keene, NH 03431) 593 grade filter paper having approximate dimensions of 1 inch by 3 inches was impregnated with Solution 1 by immersing the paper into Solution 1.
- the paper was then dried by using forced air not exceeding 25° C.
- the dried paper was then applied (laminated by pressing the paper and adhesive together) to one side of a piece of double-sided adhesive transfer tape commercially available from 3M Company (St. Paul, MN 55144).
- the laminate was then slit into sections measuring 3 inches by 0.2 inches. One section of the laminate was then attached, via the unused adhesive side to a polystyrene sheet measuring about 1.5 inches by 3 inches.
- the resulting laminate was slit parallel to its short dimension to form test devices comprising a 1.5 inch by 0.2 inch oblong polystyrene strip carrying a square of the impregnated papers at one end, and the other end serving as the handle.
- the dipstick worked as follows after contact with a urine sample: if no uniform dark gray to brown color developed, then no glutaraldehyde was present. Conversely, if any concentration of glutaraldehyde was present in the urine at a 0.1 % v/v or greater, a dark gray to brown color developed, thus confirming the presence of glutaraldehyde.
- This example pertains to a method for manufacturing the LFD Hybrid for glutaraldehyde testing.
- This method could also be utilized for any general chemistry "test pad” or pads that are currently used or will be used in the art.
- the manufacturing process includes impregnating onto an absorbent, solid carrier (e.g. paper) called in this example, the "test pad”, in the same manner as Example 1 with similar constituents.
- the test pad once impregnated, is dried, then mounted onto a solid support (nitrocellulose membrane) that is capable of transporting (through lateral flow) liquid to the test pad from the point of application of a test sample.
- the device is dipped into a liquid or the liquid sample is placed on the device at the bottom or starting point for the assay.
- the liquid migrates from the starting application point to the opposite end of the nitrocellulose lateral flow paper, during which the test pad becomes saturated with the sample.
- the reaction takes place on the test pad and color develops.
- the developed color is then compared to a color chart with known concentrations of glutaraldehyde that has the appropriate colors relative to each specific concentration of glutaraldehyde.
- the results are then recorded.
- the test pad must be an absorbent (wicking) material that permits migration of sample up the solid absorbent test pad and allows analyses and reactants to interact.
- a paper carrier matrix (S&S, 593 grade filter paper) was impregnated with the compositions of Solution 1. The paper was then cut into test pads 5 mm by 5mm. The paper was then dried using forced air. The dried impregnated test pad was then placed at approximately 35 mm (in the middle) of a 5 mm wide by 70 mm long nitrocellulose membrane (S&S FastTrackTM NC) and made fluid contact with nitrocellulose lateral flow paper.
- the nitrocellulose membrane was capable of transporting a liquid by capillary action or wicking from one end of the LFD Hybrid device to the other in approximately 60 seconds.
- the LFD Hybrid had the dimensions of 5 mm wide by 70mm long and could be backed by or in contact with strips of glass fiber filter material (e.g. S&S 30 grade) to aid in controlling the wicking action.
- glass fiber filter material e.g. S&S 30 grade
- Another solid support material can be used for this purpose.
- the sample was placed on the test device 5 mm from one end of the strip, and 35 mm from the site of where the test pad was placed in fluid contact with the strip.
- this example had the 5 mm by 5 mm impregnated test pad placed on top of the lateral flow paper and thus in fluid contact with the said paper.
- the test pad can be placed on top of the lateral flow paper making fluid contact with the lateral flow paper from the bottom side of the test pad, or the lateral flow paper can touch the paper from the side of the test pad and remain in fluid contact with the test pad. Or the lateral flow paper can rest on top of the edge of test pad or be attached and in fluid contact with the test pad in some other manner.
- runover i.e. when a reagent from one pad runs over another adjacent test pad.
- the present invention eliminates runover.
- the dipstick with multiple test pads is dipped into the urine sample.
- reagent from one pad can run over the other adjacent test pad.
- the present invention avoids this problem.
- the multiple test pads are not dipped into the urine. Instead, the urine is placed at the end of the device and travels through the lateral flow material to the reactant test pad.
- the LFD Hybrid was used as follows. A drop of urine (approximately 50 uL) was applied at the starting point or origin of the strip. The urine migrated to the opposite or terminal end of the strip. As the urine migrated across the lateral flow material
- Filter paper was successively impregnated with the following solutions and dried at 25 degrees C: Solution I Bromthymol red 1.0 g methyl red 0.5 g distilled water added to 1 L total volume of solution No buffer necessary, would affect the pH indicator's ability to response to changes in pH. A paper earner matrix (S&S, 593 grade filter paper) was impregnated with the compositions of Solution 1. The device was then made as set forth in EXAMPLE 2.
- the LFD Hybrid for pH worked in a manner similar to that of the device in EXAMPLE 2. As the urine migrated across the lateral flow material (nitrocellulose) and came into contact with the test pad (filter paper), the urine saturated the pad and caused a chemical reaction between the impregnated chemicals and the urine. This reaction was instantaneous. A color was produced that co ⁇ elated to a particular pH. By using a color chart with known concentrations and their co ⁇ esponding colors a result could be determined when the color chart is compared to the LFD Hybrid device for pH.
- the LFD Hybrid device is capable of measuring pH in the range from pH 5.0 to pH 8.0 in increments of 1.0 pH units. This constitutes the normal pH range for human urine. If the sample has a pH of 6.0 a particular color will be produced by the reaction of the urine and the chemicals impregnated on the test pad. The color on the LFD Hybrid device will match a color for pH 6.0 on the referenced color chart. Similarly, if the sample has another pH, the color for that pH will be produced. EXAMPLE 4
- EXAMPLE 5 This example illustrates a prefe ⁇ ed LFD Hybrid for Creatinine. Absorbent material is successively impregnated with the following solutions and dried at 25 degrees C: Solution 1 100 g 3,5 -Dinitrobenzoic acid
- a drop of urine (approximately 50 uL) was applied at the starting point or origin of the strip.
- the urine then migrated to the opposite or terminal end of the strip.
- the urine saturated the pad and (if positive) caused a chemical reaction between the impregnated chemicals and creatinine in the urine.
- the sample contained creatinine with a concentration of 5 to 10 mg/dL creatinine or more a purple color developed on the test pad indicating a normal urine creatinine concentration (i.e. greater than 10 mg/dL creatinine) or greater.
- Normal urine creatinine concentration can vary from 20 mg/dL to 400 mg/dL creatinine.
- This purple color was compared to a color chart showing the different colors from colorless (white background) to a dark purple depending upon the concentration of the creatinine. If the sample was negative, with a concentration of less than 10 mg/dL of creatinine present, no reaction occurred and no color developed, indicating a negative result. This negative result color was compared to a color chart showing the different colors from no color developed (negative). The reaction on the test pad was rapid thus the test results could be observed immediately.
- EXAMPLE 6 This example illustrates a LFD Hybrid device for household, off the grocery store shelf, like bleach. Absorbent material is successively impregnated with the following solutions and dried at 25 degrees C: Solution 1 1.0 M Tris HC1
- EXAMPLE 7 This example illustrates the LFD Hybrid for Oxidant.
- Oxidant as used in this example and application refers to oxidant screening; the test is not specific for any one type of oxidant and can detect, e.g. oxidants such as chromate, bleach, nitrite, and hydrogen peroxide as well as other oxidants.
- Absorbent material was successively impregnated with the following solutions and dried at 25 degrees C: Solution 1 ABTS 0.01 g/L 0.01 N Tris [hydroxymethyljaminomethane hydrochloride pH of the solution of 2.0 pH of the 1 liter solution should be acidic A paper earner matrix (S&S, 593 grade filter paper) was impregnated with the compositions of solution 1.
- the device was then made as set forth in EXAMPLE 2.
- a drop of urine (approximately 50 uL) was applied at the starting point or origin of the strip.
- the urine then migrated to the opposite or terminal end of the strip.
- the urine saturated the pad and, if positive, caused a chemical reaction between the impregnated chemicals and oxidant(s) in the urine.
- the sample was positive, with a concentration of 1.0 mg/dL Oxidants or more, an orange color developed on the test pad indicating a positive (greater than 1.0 mg/dL Oxidants) for the presence of high levels of oxidants.
- This color was compared to a color chart showing the different colors from colorless (white background) to a dark orange depending upon the concentration of the oxidant(s), if greater than 1.0 mg/dL. If the sample was negative, with a concentration of less than 1.0 mg/dL of Oxidants, no reaction occu ⁇ ed and no color developed, indicating a negative result. This negative result color was compared to a color chart showing the different colors. The reaction on the test pad was rapid thus the test results could be observed immediately.
- EXAMPLE 8 This example illustrates a LFD Hybrid for Nitrite. Absorbent material was successively impregnated with the following solutions and dried at 25 degrees C: Solution 1
- a paper ca ⁇ ier matrix (S&S, 593 grade filter paper) was impregnated with the compositions of solution 1. The device was then made as set forth in EXAMPLE 2. A drop of urine (approximately 50 uL) was applied at the starting point or origin of the strip.
- the urine then migrated to the opposite or terminal end of the strip. As the urine migrated across the lateral flow material (nitrocellulose) and came into contact with the test pad
- EXAMPLE 9 This example illustrates an LFD Hybrid device for Glutaraldehyde. Absorbent material was successively impregnated with the following solutions and dried at 25 degrees C:
- a paper ca ⁇ ier matrix (S&S, 593 grade filter paper) was impregnated with the compositions of solution 1. The device was then made as set forth in EXAMPLE 2. A drop of urine (approximately 50 uL) was applied at the starting point or origin of the strip. The urine then migrated to the opposite or terminal end of the strip. As the urine migrated across the lateral flow material (nitrocellulose) and came into contact with the test pad
- the urine saturated the pad and, if positive, caused a chemical reaction between the impregnated chemicals and glutaraldehyde in the urine. If the sample was positive, with a concentration of 10 mmol glutaraldehyde or more, a purple to gray slate color developed on the test pad indicating a positive (greater than 10 mmol of
- Glutaraldehyde for the presence of high levels of glutaraldehyde. This color was compared to a color chart showing the different colors from colorless (white background) to a slate gray depending upon the concentration of the glutaraldehyde, if greater than 10 mmol in solution. If the sample was negative, with a concentration of less than 10 mmol Glutaraldehyde present, no reaction occu ⁇ ed and no color developed, indicating a negative result. This negative result color was compared to a color chart. The reaction on the test pad was rapid, thus the test results could be observed immediately.
- EXAMPLE 10 This example illustrates a LFD Hybrid device for Calcium. Absorbent material was successively impregnated with the following solutions and dried at 25 degrees C: Solution 1 21 g of Arsenio III 1.0 M Tris HC1 dilute the above ingredients to 1 liter with distilled water the pH of the solution needs to be acidic
- a paper ca ⁇ ier matrix (S&S, 593 grade filter paper) was impregnated with the compositions of solution 1. The device was then made as set forth in EXAMPLE 2. A drop of urine (approximately 50 uL) was applied at the starting point or origin of the strip. The urine then migrated to the opposite or terminal end of the strip. As the urine migrated across the lateral flow material (nitrocellulose) and came into contact with the test pad
- EXAMPLE 11 This example illustrates a LFD Hybrid device for the detection of pH concentration in urine. Absorbent material was successively impregnated with the following solutions and dried at 25 degrees C: Solution 1 0.5 g Bromcresol Green Sodium Salt 0.5 g Thymol Blue Sodium Salt
- a paper ca ⁇ ier matrix (S&S, 593 grade filter paper) was impregnated with the compositions of solution 1.
- the paper can be impregnated by dipping the paper into Solution 1, or spraying the paper with Solution 1, or by some other suitable means.
- the paper was then cut into test pads 5 mm by 5mm in size.
- the paper was then dried using forced air.
- the 5 by 5 mm dried impregnated test pad was then placed onto a 5 mm wide by 70 mm long strip of nitrocellulose membrane (S&S FastTrackTM NC) at one end, so that the 5 by 5 mm test pad covered the last 5 mm of the 70 mm long strip and made fluid contact with nitrocellulose lateral flow paper.
- the nitrocellulose membrane was capable of transporting a liquid by capillary action or wicking from one end of the lateral flow device to the other in approximately 60 seconds. Therefore, the LFD Hybrid had the dimensions of 5 mm wide by 70mm and could be backed by or in contact with strips of glass fiber filter material (e.g. S&S 30 grade) to aid in controlling the wicking or capillary action. Other solid support material could also be used, such as paper, plastic, or vinyl or other suitable material to back the lateral flow material and provide support if needed.
- the LFD Hybrid had a starting point or origin at which the sample was placed on the test device being 5 mm from one end of the strip, and approximately 60 mm from the site of where the test pad was placed in fluid contact with the strip.
- the 5 mm by 5 mm impregnated test pad was placed on top of the lateral flow paper and thus was in fluid contact with the said paper as shown in FIG. 1.
- the starting point or origin at which the sample was placed on the test device was 5 mm from one end of the strip, and was approximately 60 mm from site where the chemically impregnated test pad was in fluid contact with the lateral flow paper as shown in FIG. 1.
- the test pad could be placed on top of the lateral flow paper making fluid contact with the lateral flow paper from the bottom side of the test pad FIG.l, or the lateral flow paper could touch the paper from the side of the test pad and remain in fluid contact with the test pad as shown in FIG. 3., or the lateral flow paper could rest on top of the edge of test pad as shown in FIG. 2, or be attached and in fluid contact with the test pad in some other manner.
- results were interpreted as follows.
- a drop of urine (approximately 50 uL) was applied to the starting point or origin of the strip.
- the urine then migrated to the opposite or terminal end of the strip.
- the urine saturated the pad and caused a chemical reaction between the impregnated chemicals in the test pad and pH (buffering) ions in the urine.
- a color developed on the test pad indicating a specific pH. For this example, a green color will appear that co ⁇ elated to a pH of 6.0. This green color was compared to a color chart showing the different colors from red pH 3.0 to a dark blue pH of 10.0 or greater.
- the color reaction of the test device produced a green color which indicated a pH of 6.0 when compared to the standard color chart which showed a green color for pH 6.0.
- the reaction on the test pad was rapid, thus the test results could be observed immediately. If for example the sample had a pH of 3.0 then the color would be red since red was the color for pH 3.0 on the standard color chart.
- EXAMPLE 12 This example illustrates an LFD Hybrid for the detection of glucose concentration in urine. Absorbent material was successively impregnated with the following solutions and dried at 25 degrees C: Solution 1
- a color developed on the test pad indicating a specific concentration of glucose For this example, a blue color appeared that co ⁇ elated to a glucose concentration of 50 mg/dL. The blue color was compared to a color chart showing the different colors from yellow (no glucose present) to dark blue, a glucose concentration of 500 mg/dL or greater. In this case, the color reaction of the test device produced a blue color which indicated a glucose concentration of 50 mg/dL when compared to the standard color chart which shows a blue color for 50 mg/dL of glucose. The reaction on the test pad was rapid and the test results could be observed between 15 and 30 seconds.
- EXAMPLE 13 This example illustrates a LFD Hybrid containing two test pads on the same device as illustrated by FIG. IB.
- the LFD Hybrid as shown in FIG. IB specifically prevents the cross contamination from test pad to test pad.
- Absorbent materials were successively impregnated with the following solutions and dried at 25 degrees C: For the pH pad: Solution 1
- the LFD Hybrid of this example depicts the detection both the glucose and pH concentration of a urine solution.
- Two paper carrier matrices S&S, 593 grade filter paper, one impregnated with the compositions of solution 1 for glucose and the other impregnated with the compositions of solution 1 for pH were prepared.
- the papers were then cut into test pads 5 mm by 5 mm in size. The papers were then dried using forced air.
- the 5 by 5 mm dried impregnated test pads were then placed onto a 5 mm by 70 mm long strip of nitrocellulose membrane (S&S FastTrackTM NC) at one end, so that the 5 by 5 mm test pads covered the last 5 mm and last 10 to 15 mm area of the nitrocellulose membrane (i.e. next to each other 5 mm apart) at the opposite end of the site where the test sample was introduced. Both pads were separated from each other by a space of 5 mm and were in fluid contact with nitrocellulose lateral flow paper.
- the nitrocellulose membrane was capable of transporting a liquid by capillary action or wicking from one end of the LFD
- the LFD Hybrid had the dimensions of 5 mm wide by 70mm and could be backed by or in contact with strips of glass fiber filter material (e.g. S&S 30 grade) to aid in controlling the wicking or capillary action, or other solid support material could be used such as paper, plastic, or vinyl or other suitable material to back the lateral flow material and provide support if needed.
- glass fiber filter material e.g. S&S 30 grade
- the embodiment depicted in this example had a starting point or origin at which the sample was placed at 5 mm from one end of the strip, and approximately 60 mm from the site of where the test pads were placed in fluid contact with the strip as shown in FIG.
- EXAMPLE 14 This example illustrates an LDF Hybrid device for urobilinogen. Absorbent material was successively impregnated with the following solutions and dried at 25 degree C: Solution 1
- the nitrocellulose membrane was capable of transporting a liquid by capillary action or wicking from one end of the lateral flow device to the other in approximately 60 seconds.
- the LFD Hybrid had the dimensions of 5 mm wide by 70mm long and could be backed by or in contact with strips of glass fiber filter material (e.g. S&S 30 grade) to aid in controlling the wicking action, or other solid support material could be used.
- glass fiber filter material e.g. S&S 30 grade
- the starting point or origin at which the sample is placed on the test device was 5 mm from one end of the strip, and 35 mm from the site of where the test pad was placed in fluid contact with the strip.
- this example had the 5 mm by 5 mm impregnated test pad placed on top of the lateral flow paper and thus in fluid contact with said paper.
- the LFD Hybrid device worked as follows.
- the starting point or origin at which the sample was placed on the test device was 5 mm from one end of the strip, and 35 mm from site where the chemically impregnated test pad was in fluid contact with the lateral flow paper.
- the test pad could be placed on top of the lateral flow paper making fluid contact with the lateral flow paper from the bottom side of the test pad, or the lateral flow paper could touch the paper from the side of the test pad and remain in fluid contact with the test pad. Or the lateral flow paper could rest on top of the edge of test pad or be attached and in fluid contact with the test pad in some other manner.
- a drop of urine (approximately 50 uL) was applied at the starting point or origin of the strip.
- the urine then migrated to the opposite or terminal end of the strip.
- the urine migrated across the lateral flow material (nitrocellulose) and came into contact with the test pad (filter page paper)
- the urine saturated the pad and, if positive, caused a chemical reaction between the impregnated chemicals and urobilinogen in the urine.
- a brick reddish color developed on the test pad indicating a positive (greater than 0.5 mg/dL urobilinogen) for the presence of positive levels of urobilinogen. This color was compared to a color chart showing the different colors from colorless (white background)) to a dark brick red depending upon the concentration of the urobilinogen.
- EXAMPLE 15 This example illustrates a LFD Hybrid device for ascorbic acid. Absorbent material was successively impregnated with the following solutions and dried at 25 degrees C: Solution 1
- a paper carrier matrix (S&S, 593 grade filter paper) was impregnated with the compositions of solution 1. The paper was then dried using forced air. The paper was then cut into test pads 5 mm by 5mm. The dried impregnated test pad was then placed at approximately 35 mm (in the middle) of a 5 mm wide by 70 mm long nitrocellulose membrane (S&S FastTrack NC) and made fluid contact with nitrocellulose lateral flow paper.
- the nitrocellulose membrane was capable of transporting a liquid by capillary action or wicking from one end of the lateral flow device to the other in approximately 60 seconds.
- the LFD Hybrid device had the dimensions of 5 mm wide by 70mm long and could be backed by or in contact with strips of glass fiber filter material (e.g. S&S 30 grade) to aid in controlling the wicking action, or other solid support material could be used.
- glass fiber filter material e.g. S&S 30 grade
- the starting point or origin at which the sample is placed on the test device was 5 mm from one end of the strip, and 35 mm from the site of where the test pad was placed in fluid contact with the strip.
- this example had the 5 mm by 5 mm impregnated test pad placed on top of the lateral flow paper and thus in fluid contact with the paper.
- the starting point or origin at which the sample was placed on the test device was 5 mm from one end of the strip, and 35 mm from site where the chemically impregnated test pad was in fluid contact with the lateral flow paper.
- the test pad was placed on top of the lateral flow paper making fluid contact with the lateral flow paper from the bottom side of the test pad, or the lateral flow paper could touch the paper from the side of the test pad and remain in fluid contact with the test pad. Or the lateral flow paper could rest on top of the edge of test pad or be attached and in fluid contact with the test pad in some other manner.
- a drop of urine (approximately 50 uL) was applied at the starting point or origin of the strip. The urine then migrated to the opposite or terminal end of the strip.
- the urine As the urine migrated across the lateral flow material (nitrocellulose) and came into contact with the test pad (filter page paper), the urine saturated the pad and, if positive, caused a chemical reaction between the impregnated chemicals and ascorbic acid in the urine. If the sample was positive, with a concentration of 10.0 mg/dL ascorbic acid or more, a decoloration of a dark blue to salmon pink color developed on the test pad indicating a positive (greater than 10.0 mg/dL ascorbic acid) for the presence of positive levels of ascorbic acid. This color could then be compared to a color chart showing the different colors from dark blue (white background on plastic strip) to a salmon pink depending upon the concentration of the ascorbic acid.
- EXAMPLE 16 This example illustrates a LFD Hybrid device for protein. Absorbent material was successively impregnated with the following solutions and dried at 25 degrees C: Solution 1 sodium citrate 13.0 g citric acid 5.0 g lauroyl sarcosine 0.7 g
- a paper carrier matrix (S&S, 593 grade filter paper) was impregnated with the composition of solution 1.
- the paper was then dried using forced air.
- the paper ca ⁇ ier matrix was then impregnated with the composition of solution 2.
- the paper was then dried.
- the paper was then cut into test pads 5 mm by 5mm.
- the dried impregnated test pad was then placed at approximately 35 mm (in the middle) of a 5 mm wide by 70 mm long nitrocellulose membrane (S&S FastTrack NC) to make fluid contact with nitrocellulose lateral flow paper.
- the nitrocellulose membrane was capable of transporting a liquid by capillary action or wicking from one end of the lateral flow device to the other in approximately 60 seconds.
- the LFD Hybrid device had the dimensions of 5 mm wide by 70mm long and could be backed by or in contact with strips of glass fiber filter material (e.g. S&S 30 grade) to aid in controlling the wicking action, or other solid support material could be used.
- glass fiber filter material e.g. S&S 30 grade
- the starting point or origin at which the sample is placed on the test device was 5 mm from one end of the strip, and 35 mm from the site of where the test pad was placed in fluid contact with the strip.
- this example had the 5 mm by 5 mm impregnated test pad placed on top of the lateral flow paper and thus in fluid contact with the paper.
- the starting point or origin at which the sample was placed on the test device was 5 mm from one end of the strip, and 35 mm from site where the chemically impregnated test pad was in fluid contact with the lateral flow paper.
- the test pad could be placed on top of the lateral flow paper making fluid contact with the lateral flow paper from the bottom side of the test pad, or the lateral flow paper could touch the paper from the side of the test pad and remain in fluid contact with the test pad. Or the lateral flow paper could rest on top of the edge of test pad or be attached and in fluid contact with the test pad in some other manner.
- a drop of urine (approximately 50 uL) was applied at the starting point or origin of the strip. The urine then migrated to the opposite or terminal end of the strip.
- the urine As the urine migrated across the lateral flow material (nitrocellulose) and came into contact with the test pad (filter page paper), the urine saturated the pad and, if positive, caused a chemical reaction between the impregnated chemicals and protein in the urine. If the sample is positive, with a concentration of 10.0 mg/dL protein or more, a light green to dark green color developed on the test pad indicating a positive (greater than 10.0 mg/dL protein) for the presence of positive levels of protein. This color could then be compared to a color chart showing the different colors from yellow (white to yellow background) to a dark green depending upon the concentration of the protein.
- EXAMPLE 17 This example illustrates a LFD Hybrid device for blood (hemoglobin). Absorbent material was successively impregnated with the following solutions and dried at 25 degrees C: Solution 1 sodium citrate 13.0 g ethylenediamine-tetraacetic acid sodium salt 5.0 g dioctyl sodium sulphosuccinate 0.7 g urea peroxide 2.3 g phosphoric acid trimorpholide 7.0 g ethanol 23.0 ml
- a paper ca ⁇ ier matrix (S&S, 593 grade filter paper) was impregnated with the composition of solution 1. The paper was then dried using forced air. The paper ca ⁇ ier matrix was impregnated with the composition of solution 2. The paper was then dried. The paper was then cut into test pads 5 mm by 5mm. The dried impregnated test pad was then placed at approximately 35 mm (in the middle) of a 5 mm wide by 70 mm long nitrocellulose membrane (S&S FastTrack NC) and made fluid contact with nitrocellulose lateral flow paper. The nitrocellulose membrane was capable of transporting a liquid by capillary action or wicking from one end of the lateral flow device to the other in approximately 60 seconds.
- the LFD Hybrid device had dimensions of 5 mm wide by 70mm long and could be backed by or in contact with strips of glass fiber filter material (e.g. S&S 30 grade) to aid in controlling the wicking action, or other solid support material could be used.
- glass fiber filter material e.g. S&S 30 grade
- this example had the 5 mm by 5 mm impregnated test pad placed on top of the lateral flow paper and thus be fluid contact with the paper.
- the starting point or origin at which the sample was placed on the test device was
- test pad 5 mm from one end of the strip, and 35 mm from site where the chemically impregnated test pad was in fluid contact with the lateral flow paper.
- the test pad could be placed on top of the lateral flow paper making fluid contact with the lateral flow paper from the bottom side of the test pad, or the lateral flow paper could touch the paper from the side of the test pad and remain in fluid contact with the test pad. Or the lateral flow paper could rest on top of the edge of test pad or be attached and in fluid contact with the test pad in some other manner.
- a drop of urine (approximately 50 uL) was applied at the starting point or origin of the strip.
- the urine then migrated to the opposite or terminal end of the strip.
- the urine saturated the pad and, if positive, caused a chemical reaction between the impregnated chemicals and blood in the urine.
- the sample was positive, with a concentration of 15.0 mcg/dL blood (hemoglobin) or more, a light green to dark green color developed on the test pad indicating a positive (greater than 15.0 mcg/dL blood) for the presence of positive levels of blood. This color was compared to a color chart showing the different colors from yellow (white to yellow background) to a dark green depending upon the concentration of the blood.
- Test pads for other analytes could be added or substituted for the test pads of Example 13. Sizes of the test pads and lateral flow material in this and other examples can obviously be changed.
- the LFD Hybrid technology herein may be used as a stand alone
- POC device or be incorporated into other testing devices.
- the examples presented in this application relate to test devices and methods of detecting adulterants in urine but could also work in other matrices such as blood, saliva, sweat extracts, serum, hair homogenates, gastric contents, cerebral spinal fluid or other fluids that come from the human body.
- the LFD Hybrid could also be used to detect specific gravity, urobilinogen, glucose, bleach, nitrite, oxidants, bilirubin, leukocyte esterase, ketone, protein, or other common urine assays.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29063199A | 1999-04-08 | 1999-04-08 | |
US290631 | 1999-04-08 | ||
US32392299A | 1999-06-02 | 1999-06-02 | |
US323922 | 1999-06-02 | ||
US54568100A | 2000-04-07 | 2000-04-07 | |
PCT/US2000/009332 WO2000062060A2 (en) | 1999-04-08 | 2000-04-07 | Method for detection of analytes in urine using lateral flow hybrid device |
US545681 | 2000-04-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1145005A2 true EP1145005A2 (de) | 2001-10-17 |
EP1145005A3 EP1145005A3 (de) | 2001-12-05 |
Family
ID=27403995
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP00921882A Withdrawn EP1145005A3 (de) | 1999-04-08 | 2000-04-07 | Verfahren zur bestimmung von analyten unter verwendung einer hybriden querflussvorrichtung |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP1145005A3 (de) |
WO (1) | WO2000062060A2 (de) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9588095B2 (en) | 2012-07-24 | 2017-03-07 | Massachusetts Institute Of Technology | Reagents for oxidizer-based chemical detection |
US9891193B2 (en) | 2012-07-24 | 2018-02-13 | Massachusetts Institute Of Technology | Reagent impregnated swipe for chemical detection |
US10345281B2 (en) | 2014-04-04 | 2019-07-09 | Massachusetts Institute Of Technology | Reagents for enhanced detection of low volatility analytes |
US10816530B2 (en) | 2013-07-23 | 2020-10-27 | Massachusetts Institute Of Technology | Substrate containing latent vaporization reagents |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6689618B1 (en) * | 2000-04-03 | 2004-02-10 | Shuenn Tzong Chen | Method and test strip of detecting oxidizing adulterant in urine |
CA2349098C (en) * | 2000-05-30 | 2011-03-01 | Integrated Biomedical Technology, Inc. | Assay for aldehyde content |
US6818452B2 (en) * | 2001-04-23 | 2004-11-16 | Branan Medical Corp. | Lateral flow contact test apparatus |
GB2377016A (en) * | 2001-06-28 | 2002-12-31 | Surescreen Diagnostics Ltd | Test strips for determining analytes in a fluid |
US7605004B2 (en) | 2001-07-18 | 2009-10-20 | Relia Diagnostic Systems Llc | Test strip for a lateral flow assay for a sample containing whole cells |
JP4566983B2 (ja) | 2003-02-24 | 2010-10-20 | バイナックス インコーポレイティッド | 乾式化学の側方流動−再構成されたクロマトグラフィー的酵素駆動式アッセイ法 |
MXPA06003183A (es) * | 2003-09-23 | 2006-06-23 | Oakville Hong Kong Co Ltd | Dispositivos de prueba de flujo lateral y metodos de uso. |
DE212004000062U1 (de) | 2003-11-14 | 2006-07-20 | Oakville Trading Hong Kong Ltd. | Probensammelbecher mit integriertem Probenanalysesystem |
US8003399B2 (en) | 2005-08-31 | 2011-08-23 | Kimberly-Clark Worldwide, Inc. | Nitrite detection technique |
CN100478671C (zh) | 2005-10-25 | 2009-04-15 | 艾康生物技术(杭州)有限公司 | 用于液体样本的检测装置和方法 |
WO2008017127A1 (en) * | 2006-08-10 | 2008-02-14 | A Capital Idea (Act) Pty Ltd | A method for detecting a pharmaceutically active agent |
US20090157024A1 (en) * | 2007-12-14 | 2009-06-18 | Kimberly-Clark Worldwide, Inc. | Hydration Test Devices |
US8901366B2 (en) * | 2007-12-14 | 2014-12-02 | Kimberly Clark Worldwide, Inc. | Urine volume hydration test devices |
US9952211B2 (en) * | 2008-06-29 | 2018-04-24 | Realbio Technologies Ltd. | Liquid-transfer device particularly useful as a capturing device in a biological assay process |
DE102009019902A1 (de) | 2009-05-05 | 2010-11-11 | Merck Patent Gmbh | Mittel und Verfahren zur Bestimmung des Aldehyd-Gehalts |
US20120115174A1 (en) * | 2009-07-17 | 2012-05-10 | Siemens Healthcare Diagnostics Inc. | Urinary trypsin inhibitors as diagnostic aid for interstitial cystitis |
US10161928B2 (en) * | 2010-07-26 | 2018-12-25 | Wellmetris, Llc | Wellness panel |
ITMI20101730A1 (it) * | 2010-09-23 | 2012-03-24 | Fond Italiana Fegato Onlus | Sistema di tipo "point of care" di misura della bilirubina totale nel plasma, in particolare di neonati |
US20130164193A1 (en) | 2011-12-22 | 2013-06-27 | Life Technologies Corporation | Sequential lateral flow capillary device for analyte determination |
KR101972420B1 (ko) * | 2016-11-02 | 2019-04-25 | 주식회사 씨스퀘어 | 소변 내에 포함된 말론디알데하이드 검출 수단 |
CN109298188A (zh) * | 2018-11-13 | 2019-02-01 | 广东众尔健生物科技有限公司 | 一种重金属和肌酐联合检测试纸条及其制备方法与应用 |
CN114199868B (zh) * | 2021-11-04 | 2023-12-08 | 成都中昆德润科技有限公司 | 一种双胍类化合物的快检方法及其应用 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4752448A (en) * | 1985-12-18 | 1988-06-21 | Keystone Diagnostics, Inc. | Drug abuse test paper |
-
2000
- 2000-04-07 WO PCT/US2000/009332 patent/WO2000062060A2/en not_active Application Discontinuation
- 2000-04-07 EP EP00921882A patent/EP1145005A3/de not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO0062060A3 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9588095B2 (en) | 2012-07-24 | 2017-03-07 | Massachusetts Institute Of Technology | Reagents for oxidizer-based chemical detection |
US9891193B2 (en) | 2012-07-24 | 2018-02-13 | Massachusetts Institute Of Technology | Reagent impregnated swipe for chemical detection |
US11237143B2 (en) | 2012-07-24 | 2022-02-01 | Massachusetts Institute Of Technology | Reagents for oxidizer-based chemical detection |
US11543399B2 (en) | 2012-07-24 | 2023-01-03 | Massachusetts Institute Of Technology | Reagents for enhanced detection of low volatility analytes |
US10816530B2 (en) | 2013-07-23 | 2020-10-27 | Massachusetts Institute Of Technology | Substrate containing latent vaporization reagents |
US10345281B2 (en) | 2014-04-04 | 2019-07-09 | Massachusetts Institute Of Technology | Reagents for enhanced detection of low volatility analytes |
Also Published As
Publication number | Publication date |
---|---|
WO2000062060A2 (en) | 2000-10-19 |
WO2000062060A3 (en) | 2001-08-16 |
EP1145005A3 (de) | 2001-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2000062060A2 (en) | Method for detection of analytes in urine using lateral flow hybrid device | |
US6537823B1 (en) | Method for detection of bromine in urine using liquid chemistry dry chemistry test pads and lateral flow | |
US4160008A (en) | Multilayered test device for determining the presence of a liquid sample component, and method of use | |
AU666821B2 (en) | Analyte detection device and process | |
EP0654659B1 (de) | Testvorrichtung mit definiertem Volumen | |
EP1082614B1 (de) | Vorrichtung und verfahren zur detektion von analyten in flüssigkeiten | |
US6818452B2 (en) | Lateral flow contact test apparatus | |
EP0441325A2 (de) | Nichtinstrumentierter Cholesterintest | |
US6602719B1 (en) | Method and device for detecting analytes in fluids | |
US5055407A (en) | Composition and method of assaying aqueous liquids for specific gravity | |
JP3476828B2 (ja) | フラクトサミンをアッセイするための多層試験デバイスおよび方法 | |
US4753890A (en) | Analytical element and method for determination of magnesium ions | |
US20030045003A1 (en) | Method for detection of the adulterant urine luckTM in urine using liquid chemistry, dry chemistry test pads, and lateral flow | |
JPS61153566A (ja) | 試薬試験具及びその形成方法 | |
JP2004325449A (ja) | 左利きにも右利きにも使える毛細管充填試験片 | |
CN104937106A (zh) | 用于监测生物流体的系统和方法 | |
US20030027350A1 (en) | Method for detection of bromine in urine using liquid chemistry, dry chemistry test pads, and lateral flow | |
US8293188B2 (en) | Detection of adulterated samples | |
EP3344140B1 (de) | Systeme für reagenzlose teststreifen | |
JPS61500152A (ja) | 流動体迅速定量分析用装置 | |
JP3536268B2 (ja) | 多項目尿試験紙 | |
US20180355402A1 (en) | Diagnostic strip for determining the amount of sarcosine, creatinine and hydrogen peroxide in a biological or environmental sample | |
JPH0755810A (ja) | 被検体を検出する装置および方法 | |
JPH05203655A (ja) | 粒子分離系を含む生物学的分析を行なうためのデバイス及び方法 | |
WO2009143601A1 (en) | Enzymatic analytical membrane, test device and method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
XX | Miscellaneous (additional remarks) |
Free format text: DERZEIT SIND DIE WIPO-PUBLIKATIONSDATEN A3 NICHT VERFUEGBAR. |
|
PUAK | Availability of information related to the publication of the international search report |
Free format text: ORIGINAL CODE: 0009015 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
17P | Request for examination filed |
Effective date: 20020218 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20021217 |